ライフサイエンスコーパス: pseudotyped

1 s linked to a GFP reporter and packaged in a pseudotyped adenoassociated viral vector (AAV2/5).

2 d entry kinetics of native viruses and their pseudotyped analogs.

3 promoters to target retrograde infection of pseudotyped and genetically modified rabies virus eviden

4 ng antibodies against infection by divergent pseudotyped and live MERS-CoV strains, as well as antibo

5 highest-affinity MAb, m336, neutralized both pseudotyped and live MERS-CoV with exceptional potency,

6 The fiber-pseudotyped and penton base constructs with RGD deleted

7 hibited IC(50) values of less than 5 nM in a pseudotyped antiviral assay, and compound 13k was demons

8 ntiviral potency comparable to 26 in the M33 pseudotyped antiviral assay.

9 on glass slides 'printed' with lentiviruses pseudotyped as vesicular stomatitis virus glycoprotein,

10 In contrast, pLV pseudotyped both glycoproteins efficiently; however, muc

11 HIV vectors pseudotyped by WEEV GP may be a useful tool for characte

12 In this study, the pseudotyped doubly labeled fluorescent reporter red/gree

13 r in the mouse nose with A. californica GP64-pseudotyped FIV (AcGP64-FIV).

14 ese findings demonstrate the utility of GP64-pseudotyped FIV lentiviral vectors for targeting hepatoc

15 We generated a GP64-pseudotyped FIV vector encoding the B domain-deleted hum

16 ind broad use given the extensive tropism of pseudotyped FIV vectors for many cell types in vitro and

17 fection mediated by the HeV glycoproteins in pseudotyped-HeV entry assays more effectively than the c

18 s and enhanced the cell entry of both SARS S-pseudotyped HIV and authentic SARS-CoV.

19 ect on human immunodeficiency virus (HIV) GP pseudotyped HIV or adeno-associated virus 2 vector entry

20 Using Ebola Zaire GP-pseudotyped HIV particles bearing a luciferase reporter

21 induced an antiviral state in astrocytes, a pseudotyped HIV viral particle, vesicular stomatitis vir

22 rameshift efficiency, and infectivity, using pseudotyped HIV-1 and HEK293T cells.

23 to CCR5-tropic HIV-1 infection but not VSV G-pseudotyped HIV-1 infection.

24 Env protein by the viral protease in MLV Env-pseudotyped HIV-1 particles bearing the MA mutations and

25 ll enhancing elements combined, the titer of pseudotyped HIV-1 particles reached almost 10(6) infecti

26 HIV-1 or murine leukemia virus Env (MLV-Env)-pseudotyped HIV-1 particles was enhanced in IFN-alpha-tr

27 or expression, as vesicular stomatitis virus-pseudotyped HIV-1 replication was also blocked by IL-12/

28 pan-neutralization against a panel of 56 Env-pseudotyped HIV-1 representing diverse subtypes of clini

29 d not lead to increased infection with VSV-G-pseudotyped HIV-1 vectors.

30 and they strongly inhibit the infectivity of pseudotyped HIV-1 virions.

31 V-2 Spike glycoprotein for the generation of pseudotyped HIV-1, murine leukemia virus (MLV), and vesi

32 ansfection production of a Sendai virus F/HN-pseudotyped HIV-1-based third generation lentiviral vect

33 potent than 4E10 against several isolates of pseudotyped HIV-1.

34 ular stomatitis virus G glycoprotein (VSV-G)-pseudotyped HIV-1.

35 na) long-term repopulating cells using VSV-G-pseudotyped HIV-based lentiviral vectors.

36 had greater susceptibility to infection with pseudotyped HIV.

37 nfirmed that Tat expression and infection of pseudotyped HIV.GFP led to increased lysosomal exocytosi

38 The titers of WEEV GP-pseudotyped human immunodeficiency virus type 1 (HIV) ra

39 We evaluated the suitability of EBOV GP pseudotyped human immunodeficiency virus type 1 (HIV-1)

40 iral activity of these compounds in an Ebola pseudotyped infection model was in the low micromolar ra

41 We have produced a pseudotyped influenza virus based on suppression of the

42 rescue HIV-1 or vesicular stomatitis virus G-pseudotyped lentivectors infection in LC.

43 oglobulin G levels, neutralizing titers in a pseudotyped lentiviral assay, and the presence of fever

44 ular stomatitis virus glycoprotein G (VSV-G)-pseudotyped lentiviral gene therapy vector could also in

45 wing transduction of T cell lines with VSV-G-pseudotyped lentiviral or gammaretroviral particles.

46 ly impaired entry of genotype 1a HCV and HCV-pseudotyped lentiviral particles (HCVpp) in Huh-7 cells

47 e of melanoma cells and targeted by the m168 pseudotyped lentiviral vector conjugated with antibody s

48 We found that the VSV-G-pseudotyped lentiviral vector failed to fuse to resting

49 ified gibbon ape leukemia virus glycoprotein-pseudotyped lentiviral vector infectivity of HSPCs, the

50 ped a novel targeting Sindbis virus envelope pseudotyped lentiviral vector, 2.2ZZ, which acquires spe

51 When pseudotyped lentiviral vectors encoding green fluorescen

52 fuse to resting CD4(+) T cells while HIV Env-pseudotyped lentiviral vectors fused, reverse transcribe

53 Rabies pseudotyped lentiviral vectors have great potential in g

54 as the major entry port of VSV and of VSV-G-pseudotyped lentiviral vectors in human and mouse cells,

55 sed to the cytoplasmic tail (CT) of gp41 and pseudotyped lentiviral vectors with them.

56 us neutralization activity was analyzed with pseudotyped lentiviral vectors, and antibody epitope map

57 Using pseudotyped lentiviral vectors, we found that a soluble

58 ral receptor TVB (TVB-NRG1), along with EnvB pseudotyped lentivirus (LV) and rabies virus (RV), to se

59 l ACE2 receptor traps neutralized SARS-CoV-2-pseudotyped lentivirus and authentic SARS-CoV-2 virus wi

60 date, NIH-CoVnb-112, blocks SARS-CoV-2 spike pseudotyped lentivirus infection of HEK293 cells express

61 dy, the VSV-G (vesicular stomatitis virus G) pseudotyped lentivirus is not and allows us to control f

62 re transduced with HLA-A2.1-expressing VSV-G-pseudotyped lentivirus or retrovirus vectors under ident

63 ransfer of Nipah virus envelope glycoprotein-pseudotyped lentivirus particles by MDCs were severely a

64 antibodies in sera of immunized mice against pseudotyped lentivirus reporter or live wild-type SARS-C

65 Neonatal intravascular injection of VSV-G pseudotyped lentivirus resulted in almost exclusive tran

66 potently reduced gene transfer of HIV-1 Env-pseudotyped lentivirus vectors and inhibited the replica

67 h are predominantly quiescent, by generating pseudotyped-lentivirus.

68 eutralizing variant hemagglutinin-expressing pseudotyped lentiviruses.

69 Vesicular stomatitis virus G protein (VSV-G)-pseudotyped LV preparations produced by transient transf

70 of TVS markedly reduces the ability of VSV-G-pseudotyped LV preparations to activate pDC.

71 Pseudotyped LV vectors containing glia-specific promoter

72 attained with subretinal injection of VSV-G pseudotyped LV vectors containing the CD44 promoter.

73 tion by vesicular stomatitis virus G protein pseudotyped M-PMV.

74 These findings indicate the utility of VSVG-pseudotyped MLV for transgenesis of S. mansoni, herald a

75 Using CERV2 Env-pseudotyped MLV reporters, we identified copper transpor

76 chistosomula were exposed to virions of VSVG-pseudotyped MLV, after which genomic DNA was extracted f

77 (ancHTenv) that could support infection of a pseudotyped modern gammaretrovirus.

78 ogs fail to support viral entry/infection of pseudotyped murine leukemia viruses expressing pathogeni

79 When pseudotyped on HIV-1 virions, the A-MLV and ASLV-A Envs

80 ed two MAbs that can strongly neutralize HCV-pseudotyped particles (HCVpp) bearing the envelope glyco

81 lycoprotein sequences were tested in the HCV pseudotyped particles (HCVpp) system.

82 ing cells much more efficiently than did HeV pseudotyped particles (HeVpp), and (iii) NiVpp but not H

83 gth NiV-G, resulted in optimal titers of NiV-pseudotyped particles (NiVpp) ( approximately 10(6) IU/m

84 The host range of the pseudotyped particles in vitro was somewhat limited, whi

85 HIV-1 efficiently forms pseudotyped particles with many gammaretrovirus glycopro

86 ne leukemia virus (MLV) Env can readily form pseudotyped particles with many retroviruses, suggesting

87 viruses to form infectious virions known as pseudotyped particles.

88 pe 1 (HIV-1) in the production of infectious pseudotyped particles.

89 infected with Ebola virus glycoprotein (GP)-pseudotyped particles.

90 ed susceptibility to both HTLV-1- and HTLV-2-pseudotyped particles.

91 Pseudotyped rAAV2/1 based vectors transduced murine isle

92 We used a pseudotyped rAAV2/5 vector to express human wild-type (w

93 We tested pseudotyped rAAVs of several common serotypes (rAAV 2/1,

94 Using pseudotyped rabies virus in a transgenic Gpr151-Cre mous

95 rons were susceptible to infection with EnvA-pseudotyped rabies virus in tumor virus A receptor trans

96 oped vesicular stomatitis virus glycoprotein-pseudotyped replication-defective simian immunodeficienc

97 We report that pseudotyped, replication-incompetent retroviruses can be

98 inity than that of sHeV-G, (ii) NiV envelope pseudotyped reporter virus (NiVpp) entered ephrinB3-expr

99 35 untreated HIV-2-infected subjects using a pseudotyped reporter virus assay.

100 seudotyped viral entry assay, where receptor-pseudotyped reporter virus was used to infect cells expr

101 hepatocytes was examined directly using HCV-pseudotyped retroviral particles (HCV-pp).

102 n of human HSCs with either FeLV-C- or RD114-pseudotyped retroviral particles may improve gene transf

103 nvelopes between PERV-A and PERV-C and using pseudotyped retroviral vectors to map the human cell tro

104 Rabbit anti-GBV-C E2 Abs neutralized HIV-1-pseudotyped retrovirus particles but not HIV-1-pseudotyp

105 e binding of soluble CD81 to immobilized HCV-pseudotyped retrovirus particles.

106 numbers of FeLV-C and GALV or RD114 and GALV-pseudotyped retroviruses for injection into fetal sheep.

107 g but that OCEV glycoprotein precursor (GPC)-pseudotyped retroviruses poorly entered 53 human cancer

108 y resistant to infection by flaviviruses and pseudotyped retroviruses, but infection can be restored

109 or inhibited GP(1,2)-mediated cell entry of pseudotyped retroviruses.

110 or the M2 proton pump, inhibits entry of HA-pseudotyped retroviruses.

111 We generated high titers of GP-pseudotyped rLCMVDeltaGP/GFP via genetic trans complemen

112 Replication of these GP-pseudotyped rLCMVDeltaGP/GFP viruses was restricted to G

113 Using GP-pseudotyped rLCMVDeltaGP/GFP, we have also obtained evid

114 Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in 293 cells express

115 Furthermore, AAV5-pseudotyped scAAV vectors mediated successful transducti

116 l vein administration of 1x10(12) vg/kg AAV5-pseudotyped scAAV-LP1-hFIXco.

117 We infused a single dose of a serotype-8-pseudotyped, self-complementary adenovirus-associated vi

118 d that the transduction of DCs in vitro with pseudotyped single-cycle SIVs expressing IFN-gamma incre

119 tion of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human i

120 The data support F/HN-pseudotyped SIV as a promising vector for pulmonary gene

121 not alter the infectivity or antigenicity of pseudotyped SIV.

122 eviously showed that IFN-gamma expression by pseudotyped SIVs does not alter viral single-cycle infec

123 ls primed with dendritic cells transduced by pseudotyped SIVs expressing high levels of IFN-gamma had

124 udy, we tested the immunogenicities of these pseudotyped SIVs in a rat model.

125 roblasts with a vesicular stomatitis virus G-pseudotyped strain of HIV-1 produced similar results, su

126 Here, we pseudotyped the SARS-CoV-2 Spike glycoprotein (SPG) on a

127 While MMLV pseudotyped the vesicular stomatitis virus G glycoprotei

128 ins in feline cells restricts FIV, impairing pseudotyped vector transduction and viral replication, b

129 ion significantly increased EBOV GP and VSVG pseudotyped vector transduction but had minimal effect o

130 The GP64-pseudotyped vector was stable in the presence of human o

131 tion of vesicular stomatitis virus GP (VSVG) pseudotyped vector.

132 RV-G pseudotyped vectors were co-transported with both the te

133 ent sheep demonstrated that FeLV-C- or RD114-pseudotyped vectors were present at significantly higher

134 infectivity or tropism from wild-type VSV-G-pseudotyped vectors.

135 ent at significantly higher levels than GALV-pseudotyped vectors.

136 genomes were packaged within F-MuLV virions (pseudotyped) very soon after infection.

137 subsequently show the specific detection of pseudotyped vesicular stomatitis virus (VSV) as a model

138 In this work, we developed a pseudotyped vesicular stomatitis virus (VSV) with a glyc

139 eudotyped retrovirus particles but not HIV-1-pseudotyped vesicular stomatitis virus particles, and E2

140 ermore, expression of HAP2 on the surface of pseudotyped vesicular stomatitis virus results in homoty

141 h wild-type PPRV were able to neutralize RPV-pseudotyped vesicular stomatitis virus.

142 EV S1(A), and infectivity assays with BCoV-S-pseudotyped vesicular stomatitis viruses.

143 These results were corroborated in a reverse-pseudotyped viral entry assay, where receptor-pseudotype

144 Pseudotyped viral entry levels primarily corroborated th

145 on of HTLV-1 virions and the titer of HTLV-1 pseudotyped viral infection in CD4(+) T cells.

146 coexpressed with GhV-G protein, and mediates pseudotyped viral particle entry.

147 as a mechanism of uptake of EBOV GP and VSVG pseudotyped viral particles.

148 dly reduced binding avidity compared to FB29-pseudotyped viral particles.

149 property, recombinant forms of VSV and VSV-G-pseudotyped viral vectors are being developed for gene t

150 VSV and for the broad applicability of VSV-G-pseudotyped viral vectors for gene transduction.

151 SARS-CoV S, followed by cell-cell fusion and pseudotyped virion infectivity assays, showed a critical

152 ify inhibitors of arenavirus infection using pseudotyped virion particles bearing the glycoproteins (

153 Moreover, pseudotyped virions carrying these N-glycan mutants had

154 , inhibited SARS-CoV S-mediated entry of the pseudotyped virions in 293T cells expressing a functiona

155 Entry of pseudotyped virions required a gD receptor and was inhib

156 that membrane fusion during the entry of the pseudotyped virions shares common requirements with the

157 idate genes were identified by using EBOV GP pseudotyped virions to transduce human tumor cell lines

158 try for Ebola virus (EBOV) glycoprotein (GP) pseudotyped virions, we used comparative gene analysis t

159 can affect VCA analyses, particularly using pseudotyped virions.

160 ells or against vesicular stomatitis virus-G pseudotyped virions.

161 the G614 variant grows to a higher titer as pseudotyped virions.

162 urine leukemia virus Env cytoplasmic tail in pseudotyped virions.

163 ck spike protein binding and/or infection by pseudotyped virus and authentic SARS-CoV-2 virus.

164 We show that SARS-CoV-2 Spike-pseudotyped virus and genuine SARS-CoV-2 infections are

165 ere infected with HIV-1/vesicular stomatitis-pseudotyped virus and stereotactically injected into the

166 ve used a human immunodeficiency virus-based pseudotyped virus as a surrogate system to dissect the r

167 We show that VSV-G-pseudotyped virus cannot fuse to unstimulated cells beca

168 susceptible to both EboV RBD binding and GP-pseudotyped virus infection than their nonadherent count

169 eletion of RFC were nonpermissive for TG35-2-pseudotyped virus infection, but the introduction of fel

170 chloroquine, as highly active inhibitors of pseudotyped virus infection.

171 ormation, despite effectively inhibiting the pseudotyped virus infection.

172 oV-2 S protein and efficiently supported the pseudotyped virus infection.

173 nd C HIV-1 strains, synergistically in a Env-pseudotyped virus neutralization assay.

174 e of the FAbs neutralized the infectivity of pseudotyped virus particles (pp) bearing the envelope gl

175 eover, these cells specifically bound FeLV-A-pseudotyped virus particles, indicating that the cDNA en

176 easurements with NAb activity measured using pseudotyped virus particles, which offer the most inform

177 er, neutralisation capacity can differ among pseudotyped virus platforms.

178 In summary, pLV-S pseudotyped virus provides a valid screening tool for th

179 d single round vescicular stomatitis virus-G pseudotyped virus replication, whereas superinfection of

180 eutralisation were greater for the VSV-based pseudotyped virus system, which is particularly importan

181 entified a new FeLV Env (TG35-2) gene from a pseudotyped virus that does not belong to any known subg

182 the SF162 virus with the JR-FL V3 created a pseudotyped virus that was hypersensitive to neutralizat

183 uses a lentivirus/vesicular stomatitis virus pseudotyped virus to engineer CD3/CD28-stimulated human

184 R followed by cloning of env genes to create pseudotyped virus to explore the link between genotypic

185 RFC cDNAs conferred susceptibility to TG35-2-pseudotyped virus when introduced into nonpermissive cel

186 l receptor TVB fused to NRG, along with EnvB-pseudotyped virus, is able to direct infection selective

187 y isolates of subtypes A, B, and C in an Env-pseudotyped-virus neutralization assay, albeit with redu

188 tically and geographically diverse HIV-1 Env-pseudotyped viruses and chronic infection plasma samples

189 The difference in sensitivity between pseudotyped viruses and primary isolates varied from 3-

190 cross-reactive VHH neutralizes SARS-CoV-2 S pseudotyped viruses as a bivalent human IgG Fc-fusion.

191 tent neutralization against EBOV and SUDV GP pseudotyped viruses as well as authentic pathogens, and

192 l of reference Env clones from among 219 Env-pseudotyped viruses assayed in TZM-bl cells with sera fr

193 Pseudotyped viruses bearing chimeric envelopes with earl

194 the infection by EBOV and EBOV glycoprotein pseudotyped viruses but not by the pseudotypes bearing t

195 Pseudotyped viruses can be used as alternatives to live

196 ing using human immunodeficiency virus-based pseudotyped viruses expressing EBOV-GP.

197 ependent entry of trypsin-treated retrovirus pseudotyped viruses expressing JMD mutant S Delta19 prot

198 00 well-characterized clade C envelope (Env)-pseudotyped viruses from early infection.

199 When tested as Env-pseudotyped viruses in a luciferase reporter gene assay,

200 he small molecule inhibited the entry of all pseudotyped viruses in vitro and the cleavage of SARS-Co

201 g of soluble HTLV-1 SU and the entry of HTLV pseudotyped viruses into non-T cells.

202 9 was active against 636 different HIV-1 Env-pseudotyped viruses of varying tropism and derived from

203 tested was significantly reduced compared to pseudotyped viruses panels.

204 tibody, 10E8V2.0/iMab, neutralized 118 HIV-1 pseudotyped viruses tested with a mean 50% inhibitory co

205 Studies of entry performed with HTLV-3 Env-pseudotyped viruses together with SU binding studies rev

206 an immunodeficiency virus type 1 (HIV-1) Env-pseudotyped viruses was created by cloning, sequencing,

207 icular stomatitis virus glycoprotein (VSV-G)-pseudotyped viruses were generated by cotransfecting 293

208 interaction, we found that Bori-15 envelope-pseudotyped viruses were significantly less sensitive th

209 from 200 southern African, clade C envelope-pseudotyped viruses with neutralization titers against 1

210 Pseudotyped viruses with V1-V2 segments from different t

211 ese VHHs neutralize MERS-CoV or SARS-CoV-1 S pseudotyped viruses, respectively.

212 V strains has mostly been measured using Env-pseudotyped viruses, which overestimate bNAb coverage an

213 for neutralizing activity using 36 HIV-1 Env-pseudotyped viruses.

214 idually by analyzing infectivity assays with pseudotyped viruses.

215 mes and subsequently replicate and spread as pseudotyped viruses.

216 face severely impairs the infectivity of Env-pseudotyped viruses.

217 induce and stabilize with soluble CD4 on Env-pseudotyped viruses.

218 lope backbone and then used them to generate pseudotyped viruses.

219 reased the titer of both HTLV-I- and HTLV-II-pseudotyped viruses.

220 itro neutralizing activity against HIV-1 Env pseudotyped viruses.

221 le for viral infection or the release of H18-pseudotyped viruses.

222 canine MDCK II cells are susceptible to H17-pseudotyped viruses.

223 arge, multi-subtype panel of 30 tier 2-3 Env-pseudotyped viruses.

224 gle-cycle assay against a large panel of Env-pseudotyped viruses.

225 pic and vesicular stomatitis virus G (VSV-G)-pseudotyped viruses.

226 icles (VLPs) as well as infectivity of GP1,2-pseudotyped viruses.

227 rnal region (MPER), using a panel of 125 Env-pseudotyped viruses.

228 Therefore, the EBOV GP pseudotyped VSV neutralisation assay reported here could

229 Virions pseudotyped with 23 of the poorly transducing GPs were c

230 We generated here high-titer LVs pseudotyped with a baboon retroviral envelope glycoprote

231 eover, Ad-5/3-kappaBF512HRE, a viral variant pseudotyped with a chimeric 5/3 fiber, exerted a strong

232 Virions, pseudotyped with a class II, SFV E1 or VEEV E, or a clas

233 intravenous injection of a lentiviral vector pseudotyped with a modified chimeric Sindbis virus envel

234 d improved photoreceptor transduction by Ad5 pseudotyped with Ad35 (Ad5/F35) or Ad37 (Ad5/F37) fiber

235 ic stem cells (HSCs) with retroviral vectors pseudotyped with amphotropic envelopes.

236 A recombinant AAV2 vector pseudotyped with an HBoV1 capsid has been developed to e

237 Jurkat cells infected by single-cycle HIV-1 pseudotyped with an HIV-1 envelope (Env) glycoprotein, b

238 However, the infectivity of HIV-1 pseudotyped with an MLV Env with the cytoplasmic tail fr

239 ave also examined infection with two viruses pseudotyped with CCR5- or CXCR4-tropic HIV-1 Env and hav

240 protein (GFP)-expressing proviral construct pseudotyped with CCR5-tropic or CXCR4-tropic envelope to

241 ocytes were resistant to hepatitis D viruses pseudotyped with CSHBV surface proteins.

242 pendent, as macrophage infections by virions pseudotyped with CXCR4 (X4)-tropic HIV-1 or vesicular st

243 compare the transduction efficiency of IDLVs pseudotyped with different envelopes (vesicular stomatit

244 neutralization of vesicular stomatitis virus pseudotyped with Ebola virus GP.

245 r envelope proteins replaced with EBOV GP or pseudotyped with EBOV GP.

246 ole of HIV-1 entry pathways by using viruses pseudotyped with either CCR5-tropic HIV-1 Env or vesicul

247 ebolavirus, as well as entry of retroviruses pseudotyped with either Lake Victoria marburgvirus or Za

248 Viruses pseudotyped with env clones representative of each mater

249 Viruses pseudotyped with Env from JR-FL and BR025 were resistant

250 e increased by the use of retroviral vectors pseudotyped with envelopes that recognize more abundant

251 1b, as well as neutralization of lentivirus pseudotyped with HCV 1a and 1b envelope glycoproteins.

252 from these antibodies, retrovirus particles pseudotyped with HCV glycoproteins (HCVpp) isolated from

253 neutralized a panel of retroviral particles pseudotyped with HCV glycoproteins from six genotypes an

254 and, as negative controls, env-minus viruses pseudotyped with HIV-1, vesicular stomatitis virus, or m

255 ted vesicular stomatitis virus (VSV) virions pseudotyped with HSV-1 essential entry glycoproteins gB,

256 Recombinant vesicular stomatitis virus pseudotyped with LFV glycoprotein (GP) adopted the recep

257 Retroviruses pseudotyped with MACV and JUNV but not GTOV glycoprotein

258 ected cells, inhibited entry of retroviruses pseudotyped with Marburg virus GP(1,2), as well as Marbu

259 The infectivity of HIV-1 pseudotyped with murine leukemia virus (MLV) Env was not

260 ion of human T cells by HIV reporter viruses pseudotyped with R5-tropic gp120 envelope proteins but h

261 ACE2, the entry of SARS-CoV or a lentivirus pseudotyped with SARS-CoV S protein in differentiated ep

262 of compounds for blocking of entry of HIV-1 pseudotyped with SARS-CoV surface glycoprotein S (SARS-S

263 The ability to generate viral particles pseudotyped with SARS-COV-2 Spike is useful for many typ

264 Finally, HIV-1 particles pseudotyped with SARS-COV-2 Spike were successfully used

265 to selectively bind to retroviral particles pseudotyped with SARS-S.

266 infusion of 1x10(12) vg/kg scAAV-LP1-hFIXco pseudotyped with serotype 8 capsid, in 3 macaques, resul

267 By contrast, viruses pseudotyped with subtype A and C Env proteins were able

268 Virus pseudotyped with subtype B Env showed robust entry via C

269 Hepatitis D virus particles pseudotyped with surface proteins of U. bilobatum HBV, b

270 activity, with mammalian retroviral vectors pseudotyped with the ASLV-A envelope glycoprotein (EnvA)

271 ere resistant to infection with a MLV vector pseudotyped with the ASLV-A envelope protein but were fu

272 Lentiviruses (LVs) pseudotyped with the chimeric GPs were evaluated in term

273 tor signaling, enhanced the entry of viruses pseudotyped with the glycoprotein of lymphocytic choriom

274 cycle simian immunodeficiency viruses (SIVs) pseudotyped with the glycoprotein of vesicular stomatiti

275 tructed and characterized single-cycle SIVs, pseudotyped with the glycoprotein of vesicular stomatiti

276 s markedly enhanced the infection of viruses pseudotyped with the GP of Machupo, Guanarito and Junin

277 t not infection by HCoV-NL63 or a retrovirus pseudotyped with the HCoV-NL63 S protein.

278 ed infection by SARS-CoV and by a retrovirus pseudotyped with the SARS-CoV spike (S) protein but not

279 f BDCA-1+ DCs are infected when the virus is pseudotyped with the vesicular stomatitis envelope VSV-G

280 imaged fusion of single retroviral particles pseudotyped with the vesicular stomatitis virus (VSV) G

281 s effect was not observed with HIV-1 virions pseudotyped with the vesicular stomatitis virus glycopro

282 the infectious entry of lentiviral particles pseudotyped with the wild-type or furin cleavage site-de

283 Reporter virus particles pseudotyped with this E protein infected cells using eit

284 Whole-virus particles pseudotyped with TR1.3 Env similarly displayed a markedl

285 y of lentiviral and gamma-retroviral vectors pseudotyped with various envelope glycoproteins.

286 ection were investigated using MLV particles pseudotyped with vesicular stomatitis virus (VSV) G glyc

287 HD5 and HD6 promoted HIV reporter viruses pseudotyped with vesicular stomatitis virus and murine l

288 HIV-1 pseudotyped with vesicular stomatitis virus envelope-inf

289 replication of human immunodeficiency virus pseudotyped with vesicular stomatitis virus G protein an

290 upon infection of mouse DCs with HIV-1 cores pseudotyped with vesicular stomatitis virus G protein.

291 function increased the infectivity of HIV-1 pseudotyped with vesicular stomatitis virus G protein.

292 the Moloney murine leukemia retrovirus (MLV) pseudotyped with vesicular stomatitis virus glycoprotein

293 e for HSPC transduction enhancement with LVs pseudotyped with vesicular stomatitis virus glycoprotein

294 lycoprotein S (SARS-S) but not that of HIV-1 pseudotyped with vesicular stomatitis virus surface glyc

295 VBIM virus particles are pseudotyped with VSV G protein, allowing efficient infec

296 T cells with lentiviral particles that were pseudotyped with VSV-G or CXCR4-tropic HIV Env and assay

297 ted by a human immunodeficiency virus vector pseudotyped with VSV-G.

298 an immunodeficiency chimeric virus particles pseudotyped with XMRV envelope protein were used to demo

299 of a green fluorescent protein (GFP) vector pseudotyped with XMRV produced GFP(+) CD4(+) T cells and

300 , the polytropic MuLV genome was extensively pseudotyped within ecotropic virions; polytropic virus r